Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21806853 | 0.87 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL25364146 | 0.87 | GRM2 (0.36) | GRM2GRM3 | |
| SCHEMBL22636144 | 0.84 | GRM2 (0.34) | GRM2GRM3 | |
| SCHEMBL25365226 | 0.84 | GRM2 (0.34) | GRM2GRM3 | |
| SCHEMBL29860800 | 0.81 | — | — | |
| SCHEMBL19593014 | 0.81 | GRM2 (0.33) | GRM2GRM3 | |
| SCHEMBL31614153 | 0.81 | GRM2 (0.33) | GRM2GRM3 | |
| SCHEMBL25762834 | 0.79 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL10179303 | 0.79 | PEPD (0.34) | GRM2GRM3 | |
| SCHEMBL20139362 | 0.79 | GRM2 (0.32) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814699-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-06-09 | — | — | US | disclosed |
| EP-3006441-A1 | NS5A INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150374668-A1 | CHEMICAL COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-31 | — | — | US | disclosed |
| US-9150587-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140371455-A1 | Chemical compounds | JANSSEN PHARMACEUTICALS INC (US) | 2014-12-18 | — | — | US | disclosed |
| US-8853416-B2 | Chemical compounds | Janssen Pharmaceuticals, Inc. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130274304-A1 | Chemical Compounds | Janssen Pharmaceuticals, Inc. | 2013-10-17 | — | — | US | disclosed |
| US-8492554-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130072690-A1 | Chemical Compounds | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2473056-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374668-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | GRM2 4204/4885GRM3 2144/4885 |
| US-20160158201-A1 | CHEMICAL COMPOUNDS | SLC10A1, UGT1A3, UGT2B7 | GRM2 4204/4885GRM3 2144/4885 |
| US-20140371455-A1 | Chemical compounds | SLC10A1, UGT1A3, UGT2B7 | GRM2 4204/4885GRM3 2144/4885 |
| US-20130072690-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | GRM2 4204/4885GRM3 2144/4885 |
| US-20130274304-A1 | Chemical Compounds | SLC10A1, UGT1A3, UGT2B7 | GRM2 4204/4885GRM3 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.